BRUKINSA

This brand name is authorized in Ecuador, Estonia, Croatia, Ireland, Israel, Poland, Romania, United States

Active ingredients

The drug BRUKINSA contains one active pharmaceutical ingredient (API):

1 Zanubrutinib UNII AG9MHG098Z - ZANUBRUTINIB

Zanubrutinib is a small-molecule inhibitor of BTK. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Zanubrutinib is used for the treatment of adult patients with mantle cell lymphoma (MCL). Read about Zanubrutinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BRUKINSA Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EL03		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EL Bruton's tyrosine kinase (BTK) inhibitors
Discover more medicines within L01EL03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 6861-MEE-1221
Country: EE	Ravimiamet	Identifier(s): 1867798
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8764
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100461024
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69200001
Country: US	FDA, National Drug Code	Identifier(s): 72579-011